All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Atrial fibrillation (AF) is the most commonly sustained tachyarrhythmia in clinical practice. It is associated with an increase in disease-related hospitalizations; a reduction in quality of life; complications such as congestive heart failure (HF), thromboembolism, and stroke; and an increased mortality risk \[[@pone.0129274.ref001]--[@pone.0129274.ref004]\]. Catheter ablation (CA) is considered an efficient mainstream therapy and potentially curative treatment for drug-refractory symptomatic AF \[[@pone.0129274.ref005], [@pone.0129274.ref006]\]. After successful ablation, patients with AF would experience improved left atrial (LA) function because of a reduction in AF burden. Nevertheless, it is noted that extensive atrial scar tissue formation produced by CA may result in adverse reactions in atrial function in AF patients. Although Jeevanantham et al. \[[@pone.0129274.ref007]\] reported successful CA for AF patients does not appear to adversely impact LA function, recent studies that investigated the impact of CA on LA function reported inconsistent results. Therefore, the purpose of this study was to update evidence regarding the effect of CA on the LA size and function in patients with AF.

Methods {#sec006}
=======

Search Strategy {#sec007}
---------------

We performed a search for articles pertaining to CA in AF patients using the key words "atrial fibrillation," "catheter ablation," "atrial size," "left atrial function," and "left atrium function." We searched for all relevant studies, without any language limitations, in PubMed, Embase, the Cochrane Library, and Web of Knowledge through May 2014. Manual searches were also performed of the bibliographies.

Inclusion and Exclusion Criteria {#sec008}
--------------------------------

The inclusion criteria were as follows: (1) randomized control trials (RCTs) or nonrandomized control trials were included; (2) follow-up imaging was performed no less than 3 months post-ablation; (3) primary outcome measurements changed regarding maximum LA volume (LAVmax), minimum LA volume (LAVmin), LA diameter (LAD), LA ejection fraction (LAEF; LAEF = \[LAVmax − LAVmin\]/LAVmax), LA active emptying fraction (LAAEF; LAAEF = {LA mid-diastolic volume just before atrial contraction \[LAVmid\]--LAVmin}/LAVmid), A wave velocity (A; *defined as the peak velocities of late transmitral flow measured by pulsed-wave Doppler echocardiography \[DE\]*), and the A\' wave velocity (A\'; *defined as the velocities of the mitral annulus during atrial contraction as measured by pulsed-wave tissue Doppler echocardiography \[TDE\]*) \[[@pone.0129274.ref008]\].

Exclusion criteria were as follows: (1) surgical ablation; (2) left ventricular ejection fraction (LVEF) of \<50% or included HF patients in each enrolled study; (3) significant valvular disease including a stenotic valvular lesion or moderate-to-heavy regurgitation after valvular replacement; (4) heart dysfunction was caused by structural heart disease or another disease; (5) the LA parameters, as detailed previously, were not reported either pre- or post-ablation; and (6) median and inter-quartile range outcomes were reported.

Data Extraction and Quality Evaluation {#sec009}
--------------------------------------

Two reviewers (Xiong and Li) assessed the quality of each study and then independently extracted data from the included studies; another author (Wang) checked the data. The extracted information were: (1) basic information regarding those studies, including country and publication year; (2) the number of patients in the study; (3) patient characteristics; (4) type of catheter ablation performed for the treatment group; and (5) outcome measures, as previously defined. Any disagreement was resolved by discussion with a third party (Wang).

To evaluate the quality of the included studies, the following aspects had been performed, including (1) research design; (2) the representativeness of the enrolled patients; (3) the bias of loss to follow-up; and (4) other biases and limitations.

Statistical Analysis {#sec010}
--------------------

Cochrane Review Manager Version 5.2 and Stata 12.0 were used to perform the statistical analysis. Weighted mean differences (WMDs) with 95% confidence intervals (CIs) were used for expressing continuous outcomes. Statistical heterogeneity was tested using the χ^2^ test and was quantified using the I^2^ statistic; significant heterogeneity was defined as a *P* of \<0.10 or an I^2^ of \>50%. Data were pooled using a fixed effect or random effect model, based on whether the absence of significant heterogeneity existed. If the absence of heterogeneity was significant, the fixed effect model was performed, but if not, the random effect model was performed. Publication bias was evaluated using Egger's test and Begg's funnel plot with Stata 12.0; statistical significance was defined as a *P* of \<0.05.

Results {#sec011}
=======

Study Characteristics {#sec012}
---------------------

We identified 1566 references from electronic databases using the previously described strategy. According to the inclusion criteria, 92 citations were retrieved and required further evaluation after screening the title, abstract, or both. Forty-one reviews and 14 case reports were excluded. Two studies reported median and inter-quartile range outcomes; 6 studies included surgical ablation; 2 studies had a follow-up of \<3 months; and 2 studies included HF patients. Finally, 25 studies (2040 enrolled patients) were selected for this meta-analysis \[[@pone.0129274.ref009]--[@pone.0129274.ref033]\]. The selection process is demonstrated in a flow chart ([Fig 1](#pone.0129274.g001){ref-type="fig"}). The characteristics of each included study are listed in [Table 1](#pone.0129274.t001){ref-type="table"}. The primary results of each included study are shown in [Table 2](#pone.0129274.t002){ref-type="table"}.

![Flow chart of the literature search and study selection processes.](pone.0129274.g001){#pone.0129274.g001}
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###### Characteristics of the studies included in the current review.

![](pone.0129274.t001){#pone.0129274.t001g}

  Study                                Area          Number of Patients   Age (yrs)                                   Men     Paroxysmal AF Persistent AF Permanent AF   Follow-Up (mon)   Duration of AF                                    Comorbidities   Medications             Type of Ablation   Type of Imaging   LVEF (%)                                     Patients with Recurrence   Success Rate
  ------------------------------------ ------------- -------------------- ------------------------------------------- ------- ------------------------------------------ ----------------- ------------------------------------------------- --------------- ----------------------- ------------------ ----------------- -------------------------------------------- -------------------------- --------------
  Dagres \[[@pone.0129274.ref009]\]    Greece        289                  56±9                                        214     289                                        12                68±58mon                                          HTN (43%);      NA                      PVCA               TTE               62±10                                        123                        166/289
  2009                                                                                                                (74%)   NA                                                                                                             DM (5%);                                                                                                                                             (57%)
                                                                                                                              NA                                                                                                             CAD (5%)                                                                                                                                             
  Erdei \[[@pone.0129274.ref010]\]     Hungary       36                   57±9                                        26      36                                         12                6.7±7.3yrs                                        HTN (75%);      AAD                     CCA                TTE               63±5                                         21                         15/36
  2012                                                                                                                (72%)   NA                                                                                                             IHD (11%);                                                                                                                                           (42%)
                                                                                                                              NA                                                                                                             OB (28%)                                                                                                                                             
  Hof \[[@pone.0129274.ref011]\]       Netherlands   206                  57±10                                       165     114                                        16                7±6yrs                                            HTN (35%);      AAD                     PVAI               CMR               NA                                           37                         169/206
  2013                                                                                                                (80%)   92                                                                                                             IHD (10%)       (Class I and III)                                                                                                                    (82%)
                                                                                                                              NA                                                                                                                                                                                                                                                                  
  Jahnke \[[@pone.0129274.ref012]\]    Germany       41                   57±10                                       28      25                                         12                NA                                                HTN (66%);      NA                      PVI                CMR               58±5                                         10                         31/41
  2011                                                                                                                (68%)   16                                                                                                             DM (5%);                                                                                                                                             (76%)
                                                                                                                              NA                                                                                                             CAD (20%);                                                                                                                                           
                                                                                                                                                                                                                                             HLP (59%)                                                                                                                                            
  Machino-                             Japan         123                  60±9                                        104     NA                                         18                5.2±4.3yrs                                        HTN (56%);      AAD                     PVI                TTE               NA                                           45                         78/123
  Ohtsuka\[[@pone.0129274.ref013]\]                                                                                   (85%)   123                                                                                                            DM (7%);                                                                                                                                             (63%)
  2013                                                                                                                        NA                                                                                                             CAD (6%)                                                                                                                                             
  Masuda \[[@pone.0129274.ref014]\]    Japan         115                  62±10                                       82      92                                         3                 44.6±51.9mon                                      HTN (50%);      AAD                     PVCA               MDCT              67±7                                         32                         83/115
  2012                                                                                                                (71%)   23                                                                                                             DM (13%)                                                                                                                                             (72%)
                                                                                                                              NA                                                                                                                                                                                                                                                                  
  Montserrat                           Spain         158                  53±11                                       120     77                                         6                 52±34mon                                          HTN (44%)       AAD                     RFCA               TTE               59±9                                         82                         76/158
  \[[@pone.0129274.ref015]\] 2011                                                                                     (76%)   77                                                                                                                                                                                                                                                                  (48%)
                                                                                                                              NA                                                                                                                                                                                                                                                                  
  Nori \[[@pone.0129274.ref016]\]      America       29                   54±11                                       18      16                                         3                 4.1±3.4yrs[\*](#t001fn001){ref-type="table-fn"}   HTN (48%);      NA                      PVAI               CMR               63±11[\*](#t001fn001){ref-type="table-fn"}   NA                         NA
  2009                                                                                                                (62%)   13                                                           2.0±1.0yrs[\#](#t001fn002){ref-type="table-fn"}   DM (17%);                                                                    60±10[\#](#t001fn002){ref-type="table-fn"}                              
                                                                                                                              NA                                                                                                             CAD (38%);                                                                                                                                           
                                                                                                                                                                                                                                             HLP (55%)                                                                                                                                            
  Rodrigues                            Brazil        28                   53±13                                       22      28                                         8                 6 yrs                                             HTN (39%)       Amiodarone;             PVCA               TTE               NA                                           11                         17/28
  \[[@pone.0129274.ref017]\] 2009                                                                                     (79%)   NA                                                           (3mon-20yrs)                                                      Propafenone;                                                                                                                         (61%)
                                                                                                                              NA                                                                                                                             β-blocker                                                                                                                            
  Teh \[[@pone.0129274.ref018]\]       Australia     11                   59±8                                        8       7                                          10                5.6±4.8yrs                                        NA              NA                      RFCA               TTE               60±7                                         NA                         NA
  2012                                                                                                                (73%)   4                                                                                                                                                                                                                                                                   
                                                                                                                              NA                                                                                                                                                                                                                                                                  
  Tops \[[@pone.0129274.ref019]\]      Netherlands   148                  54±9                                        117     112                                        13                5.3±4.5yrs                                        HTN (42%);      AAD;                    PVI                TTE               57±7                                         49                         99/148
  2011                                                                                                                (79%)   36                                                                                                             CAD (6%)        ACEI (49%)                                                                                                                           (67%)
                                                                                                                              NA                                                                                                                                                                                                                                                                  
  Yoshida \[[@pone.0129274.ref020]\]   Japan         67                   64±8                                        58      34                                         6                 NA                                                NA              NA                      PVI                TTE               NA                                           11                         56/67
  2013                                                                                                                (87%)   33                                                                                                                                                                                                                                                                  (84%)
                                                                                                                              NA                                                                                                                                                                                                                                                                  
  Reant \[[@pone.0129274.ref024]\]     France        48                   53±9[\*](#t001fn001){ref-type="table-fn"}   40      37                                         11                6±5yrs[\*](#t001fn001){ref-type="table-fn"}       NA              β-blocker (29%);        PVI                TTE               62±5[\*](#t001fn001){ref-type="table-fn"}    13                         35/48
  2005                                                                    55±11[&](#t001fn003){ref-type="table-fn"}   (83%)   NA                                                           12±9yrs[&](#t001fn003){ref-type="table-fn"}                       Amiodarone(2%);                                              53±8[&](#t001fn003){ref-type="table-fn"}                                (73%)
                                                                                                                              11[&](#t001fn003){ref-type="table-fn"}                                                                                         Flecainide (14%)                                                                                                                     
  Delgado                              Spain         34                   53±13                                       24      23                                         6                 90±72mon                                          HTN (24%)       AAD                     CPVA               3D-TTE            NA                                           13                         21/34
  \[[@pone.0129274.ref029]\] 2008                                                                                     (70%)   6                                                                                                                                                                                                                                                                   (62%)
                                                                                                                              5                                                                                                                                                                                                                                                                   
  Verma \[[@pone.0129274.ref027]\]     America       67                   56±10                                       49      40                                         6                 5.8±5.1yrs                                        HTN (31%);      AAD                     PVAI               TTE,              50±13                                        NA                         NA
  2006                                                                                                                (73%)   27                                                                                                             DM (9%);                                                   CT                                                                                        
                                                                                                                              NA                                                                                                             CAD (19%);                                                                                                                                           
                                                                                                                                                                                                                                             VHD (15%)                                                                                                                                            
  Lemola \[[@pone.0129274.ref023]\]    America       36                   55±11                                       24      27                                         5                 5±4yrs                                            CAD (9%)        NA                      LACA               CT                56±5                                         NA                         NA
  2005                                                                                                                (67%)   NA                                                                                                                                                                                                                                                                  
                                                                                                                              9[&](#t001fn003){ref-type="table-fn"}                                                                                                                                                                                                                               
  Perea \[[@pone.0129274.ref033]\]     Spain         55                   52±11                                       44      41                                         12                8.4±8yrs                                          HTN (22%);      AAD                     CPVA               CMR               60±9                                         17                         38/55
  2008                                                                                                                (80%)   14                                                                                                             SHD (16%)                                                                                                                                            (69%)
                                                                                                                              NA                                                                                                                                                                                                                                                                  
  Muller \[[@pone.0129274.ref032]\]    Switzerland   91                   59±8                                        79      72                                         6                 6.4±5.8yrs                                        HTN (33%);      ACEI and/or ARB(30%);   PVI                TTE               NA                                           21                         70/91
  2008                                                                                                                (87%)   11                                                                                                             IHD (7%)        Diuretic (15%);                                                                                                                      (77%)
                                                                                                                              8                                                                                                                              Amiodarone (24%);                                                                                                                    
                                                                                                                                                                                                                                                             Sotalol (12%);                                                                                                                       
                                                                                                                                                                                                                                                             Ic (31%);                                                                                                                            
                                                                                                                                                                                                                                                             β-blocker (43%)                                                                                                                      
  Marsan \[[@pone.0129274.ref031]\]    Netherlands   57                   56±9                                        44      43                                         8                 4.6±4.1yrs                                        HTN (44%);      Amiodarone;             RFCA               3D-TTE            57±9                                         19                         38/57
  2008                                                                                                                (77%)   14                                                                                                             DM (11%);       Propafenone;                                                                                                                         (67%)
                                                                                                                              NA                                                                                                             CAD (5%)        Flecainide;                                                                                                                          
                                                                                                                                                                                                                                                             Sotalol;                                                                                                                             
                                                                                                                                                                                                                                                             ACEI and/or ARBs(46%)                                                                                                                
  Beukema                              Netherlands   105                  53±10                                       88      52                                         15                6±5.1yrs[\*](#t001fn001){ref-type="table-fn"}     HTN (26%);      AAD                     PVI                TTE               54±4                                         34                         71/105
  \[[@pone.0129274.ref022]\] 2005                                                                                     (84%)   53                                                           7.6±6yrs[\#](#t001fn002){ref-type="table-fn"}     DM (5%)                                                                                                                                              (68%)
                                                                                                                              NA                                                                                                                                                                                                                                                                  
  Choi \[[@pone.0129274.ref028]\]      Korea         33                   56±10                                       27      21                                         3                 63±47mon                                          HTN (21%);      ACEI or ARB (24%);      RFCA               TTE               53±6                                         NA                         NA
  2008                                                                                                                (82%)   12                                                                                                             DM (6%);        CCB (30%);                                                                                                                           
                                                                                                                              NA                                                                                                             CAD (6%)        β-blocker (15%);                                                                                                                     
                                                                                                                                                                                                                                                             Amiodarone (30%);                                                                                                                    
                                                                                                                                                                                                                                                             Propafenone (30%);                                                                                                                   
                                                                                                                                                                                                                                                             Flecainide (6%)                                                                                                                      
  Liu \[[@pone.0129274.ref030]\]       China         120                  60±9                                        80      120                                        12                2.6±1.4yrs                                        NA              Amiodarone;             CPVA               TTE               67±3                                         42                         78/120
  2008                                                                                                                (83%)   NA                                                                                                                             Losartan                SPVI                                                                                                         (65%)
                                                                                                                              NA                                                                                                                                                                                                                                                                  
  Tops \[[@pone.0129274.ref026]\]      Netherlands   57                   53±8                                        45      35                                         3                 6±5yrs                                            HTN (30%);      AAD                     RFCA               TTE               55±7                                         18                         39/57
  2006                                                                                                                (79%)   18                                                                                                             CAD (7%);                                                                                                                                            (68%)
                                                                                                                              4                                                                                                              VHD (11%)                                                                                                                                            
  Lemola \[[@pone.0129274.ref021]\]    America       41                   54±12                                       33      25                                         4                 5±3yrs                                            HTN (21%);      NA                      LACA               CT                55±8                                         8                          33/41
  2004                                                                                                                (80%)   NA                                                                                                             SHD (41%)                                                                                                                                            (80%)
                                                                                                                              16                                                                                                                                                                                                                                                                  
  Tsao \[[@pone.0129274.ref025]\]      China         45                   60±13                                       36      45                                         21                NA                                                NA              AAD                     PVI                CMR               NA                                           10                         35/45
  2005                                 Taiwan                                                                         (80%)   NA                                                                                                                                                                                                                                                                  (77%)
                                                                                                                              NA                                                                                                                                                                                                                                                                  

\* Paroxysmal Atrial Fibrillation

\# Persistent Atrial Fibrillation

& Chronic Atrial Fibrillation

NA = Not Available; mon = months; yrs = years

HTN = Hypertension; DM = Diabetes Mellitus; CAD = Coronary Artery Disease; OB = Obesity; IHD = Ischemic Heart Disease; HLP = Hyperlipidemia; VHD = Valvular Heart Disease; SHD = Structural heart disease.

ACEI = Angiotensin Converting Enzyme Inhibitors; ARB = Angiotensin Receptor Blocker; CCB = Calcium-channel Blocker; AAD = Anti-Arrhythmic Drugs.

RFCA = Radiofrequency Catheter Ablation; CCA = Cryoballoon Catheter Ablation; PVI = Pulmonary vein isolation; PVAI = Pulmonary Vein Antrum Isolation; CPVA/PVCA = Circumferential Pulmonary Vein Catheter Ablation; SPVI = Segmental Pulmonary Vein Isolation; LACA = Radiofrequency Left Atrial Circumferential Ablation. CMR = Cardiac Magnetic Resonance Imaging; TTE = Transthoracic Echocardiography; TEE = Transesophageal Echocardiography; MDCT = Multidetector Computed Tomography.

Atrial fibrillation recurrence is defined as documented by body surface 12-lead electrocardiogram (ECG) or 24-hour Holter ECG lasting 30 seconds, despite being symptomatic or not, at any time from 3 months after catheter ablation.

10.1371/journal.pone.0129274.t002

###### Primary outcome variables before and after ablation.

![](pone.0129274.t002){#pone.0129274.t002g}

  Study                               LAD                                                  LAD                                                  LAVmax                                                LAVmax                                                LAVmin                                            LAVmin                                            LAEF                                              LAEF                                              LAAEF                                            LAAEF                                           A Wave                                       A Wave                                       A\' Wave                                             A\' Wave                                             
  ----------------------------------- ---------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------- ------------------------------------------------- ------------------------------------------------- ------------------------------------------------- ------------------------------------------------- ------------------------------------------------ ----------------------------------------------- -------------------------------------------- -------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ----
  Dagres \[[@pone.0129274.ref009]\]   42±6[\*](#t002fn001){ref-type="table-fn"}            41±5[\*](#t002fn001){ref-type="table-fn"}            NA                                                    NA                                                    NA                                                NA                                                NA                                                NA                                                NA                                               NA                                              59±23[\*](#t002fn001){ref-type="table-fn"}   53±12[\*](#t002fn001){ref-type="table-fn"}   NA                                                   NA                                                   
  2009                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Erdei \[[@pone.0129274.ref010]\]    54±6(NR) [\*](#t002fn001){ref-type="table-fn"}       56±5(NR) [\*](#t002fn001){ref-type="table-fn"}       67±20(NR) [\*](#t002fn001){ref-type="table-fn"}       69±15(NR) [\*](#t002fn001){ref-type="table-fn"}       30±12(NR) [\*](#t002fn001){ref-type="table-fn"}   32±11(NR) [\*](#t002fn001){ref-type="table-fn"}   55±8(NR) [\*](#t002fn001){ref-type="table-fn"}    55±9(NR) [\*](#t002fn001){ref-type="table-fn"}    NA                                               NA                                              NA                                           NA                                           10.7±2.7(NR) [\*](#t002fn001){ref-type="table-fn"}   10.8±3.1(NR) [\*](#t002fn001){ref-type="table-fn"}   
  2012                                55±5(R) [\*](#t002fn001){ref-type="table-fn"}        59±6(R) [\*](#t002fn001){ref-type="table-fn"}        73±23(R) [\*](#t002fn001){ref-type="table-fn"}        81±24(R) [\*](#t002fn001){ref-type="table-fn"}        38±19(R) [\*](#t002fn001){ref-type="table-fn"}    44±20(R) [\*](#t002fn001){ref-type="table-fn"}    48±11(R) [\*](#t002fn001){ref-type="table-fn"}    47±11(R) [\*](#t002fn001){ref-type="table-fn"}                                                                                                                                                                                               9.8±2.1(R) [\*](#t002fn001){ref-type="table-fn"}     10.2±2.7(R) [\*](#t002fn001){ref-type="table-fn"}    
  Hof \[[@pone.0129274.ref011]\]      NA                                                   NA                                                   116.6±27.7[\*](#t002fn001){ref-type="table-fn"}       104.1±25.3[\*](#t002fn001){ref-type="table-fn"}       62.8±20[\*](#t002fn001){ref-type="table-fn"}      57.9±18.9[\*](#t002fn001){ref-type="table-fn"}    43.8±9.3                                          41.2±9.6                                          27.9±9.5                                         25.4±9.5                                        NA                                           NA                                           NA                                                   NA                                                   
  2013                                                                                                                                          135.6±35.9[\#](#t002fn002){ref-type="table-fn"}       121.5±34.8[\#](#t002fn002){ref-type="table-fn"}       80.2±32.1[\#](#t002fn002){ref-type="table-fn"}    73.8±27.1[\#](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                             
  Jahnke                              NA                                                   NA                                                   98±18(NR)                                             83.7±19.3(NR)                                         68.2±23.7(NR)                                     50.4±18.4(NR)                                     31.4±17.3(NR)                                     40.7±13.2(NR)                                     NA                                               NA                                              NA                                           NA                                           NA                                                   NA                                                   
  \[[@pone.0129274.ref012]\] 2011                                                                                                               116.7±20.3(R)                                         108±19.8(R)                                           80.2±24.9(R)                                      71.3±23.8(R)                                      31.8±15.2(R)                                      34.9±13.9(R)                                                                                                                                                                                                                                                                                                                                           
  Machino-                            NA                                                   NA                                                   48±25(NR) [\#](#t002fn002){ref-type="table-fn"}       34±16(NR) [\#](#t002fn002){ref-type="table-fn"}       40±19(NR) [\#](#t002fn002){ref-type="table-fn"}   23±12(NR) [\#](#t002fn002){ref-type="table-fn"}   24±17(NR) [\#](#t002fn002){ref-type="table-fn"}   36±14 NR) [\#](#t002fn002){ref-type="table-fn"}   NA                                               NA                                              54±12[\#](#t002fn002){ref-type="table-fn"}   63±19[\#](#t002fn002){ref-type="table-fn"}   NA                                                   NA                                                   
  Ohtsuka                                                                                                                                       57±23(R) [\#](#t002fn002){ref-type="table-fn"}        59±22(R) [\#](#t002fn002){ref-type="table-fn"}        47±16(R) [\#](#t002fn002){ref-type="table-fn"}    49±20(R) [\#](#t002fn002){ref-type="table-fn"}    21±16(R) [\#](#t002fn002){ref-type="table-fn"}    17±14(R) [\#](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                         
  \[[@pone.0129274.ref013]\] 2013                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Masuda                              NA                                                   NA                                                   57.3±17.7[\*](#t002fn001){ref-type="table-fn"}        53.2±14.9[\*](#t002fn001){ref-type="table-fn"}        NA                                                NA                                                47.4±11.8[\*](#t002fn001){ref-type="table-fn"}    44.9±10.6[\*](#t002fn001){ref-type="table-fn"}    NA                                               NA                                              NA                                           NA                                           NA                                                   NA                                                   
  \[[@pone.0129274.ref014]\] 2012                                                                                                               65.8±28.4[\#](#t002fn002){ref-type="table-fn"}        53.4±22.8[\#](#t002fn002){ref-type="table-fn"}                                                                                                            32.7±11.4[\#](#t002fn002){ref-type="table-fn"}    39.1±11.5[\#](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                         
  Montserrat                          42±6[\*](#t002fn001){ref-type="table-fn"}            41±6[\*](#t002fn001){ref-type="table-fn"}            53±16[\*](#t002fn001){ref-type="table-fn"}            47±15[\*](#t002fn001){ref-type="table-fn"}            30±12[\*](#t002fn001){ref-type="table-fn"}        28±11[\*](#t002fn001){ref-type="table-fn"}        44±16[\*](#t002fn001){ref-type="table-fn"}        40±13[\*](#t002fn001){ref-type="table-fn"}        37±23[\*](#t002fn001){ref-type="table-fn"}       44±25[\*](#t002fn001){ref-type="table-fn"}      NA                                           NA                                           NA                                                   NA                                                   
  \[[@pone.0129274.ref015]\] 2011     44±6[\#](#t002fn002){ref-type="table-fn"}            43±5[\#](#t002fn002){ref-type="table-fn"}            64±20[\#](#t002fn002){ref-type="table-fn"}            56±18[\#](#t002fn002){ref-type="table-fn"}            46±18[\#](#t002fn002){ref-type="table-fn"}        39±16[\#](#t002fn002){ref-type="table-fn"}        28±16[\#](#t002fn002){ref-type="table-fn"}        31±17[\#](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                             
  Nori \[[@pone.0129274.ref016]\]     NA                                                   NA                                                   37±6.4[\*](#t002fn001){ref-type="table-fn"}           28.5±5.9[\*](#t002fn001){ref-type="table-fn"}         19.7±5.7[\*](#t002fn001){ref-type="table-fn"}     16.3±5.9[\*](#t002fn001){ref-type="table-fn"}     47.3±10.1[\*](#t002fn001){ref-type="table-fn"}    42.7±9.4[\*](#t002fn001){ref-type="table-fn"}     33.4±8.3[\*](#t002fn001){ref-type="table-fn"}    26.2±7.9[\*](#t002fn001){ref-type="table-fn"}   NA                                           NA                                           NA                                                   NA                                                   
  2009                                                                                                                                          41.4±8.7[\#](#t002fn002){ref-type="table-fn"}         36.7±10[\#](#t002fn002){ref-type="table-fn"}          31.7±9.3[\#](#t002fn002){ref-type="table-fn"}     24±8.8[\#](#t002fn002){ref-type="table-fn"}       24.1±11.8[\#](#t002fn002){ref-type="table-fn"}    34.8±10.2[\#](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                         
  Rodrigues                           41±7[\*](#t002fn001){ref-type="table-fn"}            40±6[\*](#t002fn001){ref-type="table-fn"}            56±21(NR)[\*](#t002fn001){ref-type="table-fn"}        58±20(NR)[\*](#t002fn001){ref-type="table-fn"}        30±15[\*](#t002fn001){ref-type="table-fn"}        34±15[\*](#t002fn001){ref-type="table-fn"}        47±8[\*](#t002fn001){ref-type="table-fn"}         43±8[\*](#t002fn001){ref-type="table-fn"}         NA                                               NA                                              55±15[\*](#t002fn001){ref-type="table-fn"}   58±19[\*](#t002fn001){ref-type="table-fn"}   7.9±2.3[\*](#t002fn001){ref-type="table-fn"}         8.1±2.8[\*](#t002fn001){ref-type="table-fn"}         
  \[[@pone.0129274.ref017]\] 2009                                                                                                               53±14(R)[\*](#t002fn001){ref-type="table-fn"}         57±20(R)[\*](#t002fn001){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Teh \[[@pone.0129274.ref018]\]      45±7                                                 42±6                                                 76±30                                                 63±23                                                 NA                                                NA                                                NA                                                NA                                                NA                                               NA                                              NA                                           NA                                           NA                                                   NA                                                   
  2012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Tops \[[@pone.0129274.ref019]\]     43±4                                                 40±4                                                 31±7                                                  21±6                                                  19±6                                              12±5                                              41±14                                             46±11                                             NA                                               NA                                              NA                                           NA                                           NA                                                   NA                                                   
  2011                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Yoshida                             38±7[\*](#t002fn001){ref-type="table-fn"}            40±8[\*](#t002fn001){ref-type="table-fn"}            NA                                                    NA                                                    NA                                                NA                                                NA                                                NA                                                NA                                               NA                                              NA                                           NA                                           NA                                                   NA                                                   
  \[[@pone.0129274.ref020]\] 2013     41±6[\#](#t002fn002){ref-type="table-fn"}            40±8[\#](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Reant \[[@pone.0129274.ref024]\]    59.7±7.3[\*](#t002fn001){ref-type="table-fn"}        53.19±7.7[\*](#t002fn001){ref-type="table-fn"}       NA                                                    NA                                                    NA                                                NA                                                NA                                                NA                                                30.9±13.5[\*](#t002fn001){ref-type="table-fn"}   34±11.3[\*](#t002fn001){ref-type="table-fn"}    NA                                           NA                                           NA                                                   NA                                                   
  2005                                68.4±8.1[&](#t002fn003){ref-type="table-fn"}         60.68±6.5[&](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                            5.4±3.6[&](#t002fn003){ref-type="table-fn"}      21.8±11[&](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                                         
  Delgado                             40±6(NR)                                             39±6(NR)                                             50±11(NR)                                             45±10(NR)                                             26±13(NR)                                         24±8(NR)                                          49±19(NR)                                         48±18(NR)                                         25±21(NR)                                        26±21(NR)                                       31±27(NR)                                    30±26(NR)                                    NA                                                   NA                                                   
  \[[@pone.0129274.ref029]\] 2008     42±7(R)                                              43±9(R)                                              64±19(R)                                              53±22(R)                                              32±12(R)                                          30±15(R)                                          49±14(R)                                          43±13(R)                                          23±19(R)                                         18±12(R)                                        22±36(R)                                     42±16(R)                                                                                                                                               
  Verma \[[@pone.0129274.ref027]\]    45.9±10.2                                            44.4±4.5                                             94.5±28.1                                             85.8±18.2                                             78.6±23.8                                         66.8±13.9                                         16.7±5.8                                          22.1±5.4                                          NA                                               NA                                              42.8±20.9                                    61.9±17.3                                    NA                                                   NA                                                   
  2006                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Lemola                              NA                                                   NA                                                   121±40[\*](#t002fn001){ref-type="table-fn"}           95±30[\*](#t002fn001){ref-type="table-fn"}            87±39[\*](#t002fn001){ref-type="table-fn"}        78±27[\*](#t002fn001){ref-type="table-fn"}        32±13[\*](#t002fn001){ref-type="table-fn"}        21±8[\*](#t002fn001){ref-type="table-fn"}         NA                                               NA                                              NA                                           NA                                           NA                                                   NA                                                   
  \[[@pone.0129274.ref023]\] 2005                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Perea \[[@pone.0129274.ref033]\]    NA                                                   NA                                                   98±19.9(NR)                                           84.9±17.1(NR)                                         58.6±16.1(NR)                                     52.2±12.1(NR)                                     40.2±11.5(NR)                                     38.1±9.8(NR)                                      NA                                               NA                                              NA                                           NA                                           NA                                                   NA                                                   
  2008                                                                                                                                          126.2±32.8(R)                                         103.5±28.1(R)                                         78.4±22.2(R)                                      75.8±24.3(R)                                      37.4±10.1(R)                                      26.9±10.2(R)                                                                                                                                                                                                                                                                                                                                           
  Muller \[[@pone.0129274.ref032]\]   56±8                                                 53±7                                                 59.6±21.3                                             51±15.5                                               NA                                                NA                                                NA                                                NA                                                NA                                               NA                                              59.7±20.4                                    59±16.1                                      8.9±2.9                                              9.8±3.4                                              
  2008                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Marsan                              NA                                                   NA                                                   26±8(NR)                                              23±7(NR)                                              13±5(NR)                                          10±4(NR)                                          52±10(NR)                                         58±10(NR)                                         22±8(NR)                                         33±9(NR)                                        NA                                           NA                                           NA                                                   NA                                                   
  \[[@pone.0129274.ref031]\] 2008                                                                                                               31±8(R)                                               32±8(R)                                               16±7(R)                                           18±6(R)                                           47±13(R)                                          42±11(R)                                          24±7(R)                                          15±9(R)                                                                                                                                                                                                                                             
  Beukema                             40.5±4.4(NR) [\*](#t002fn001){ref-type="table-fn"}   37.5±3.5(NR) [\*](#t002fn001){ref-type="table-fn"}   NA                                                    NA                                                    NA                                                NA                                                NA                                                NA                                                NA                                               NA                                              NA                                           NA                                           NA                                                   NA                                                   
  \[[@pone.0129274.ref022]\] 2005     44±5.8(NR) [\#](#t002fn002){ref-type="table-fn"}     40±4.5(NR) [\#](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                      45±6.5(R) [\#](#t002fn002){ref-type="table-fn"}      49±5.4(R) [\#](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Choi \[[@pone.0129274.ref028]\]     41±5.4                                               39±6.4                                               63.4±20.7                                             50.7±16.6                                             43.8±18.2                                         35.1±12.9                                         31.8±12.8                                         30.9±10                                           NA                                               NA                                              60.7±22.7                                    44.8±16.7                                    9.7±1.9                                              7.6±1.6                                              
  2008                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Liu                                 CPVA                                                 33.8±3.6(NR) [\*](#t002fn001){ref-type="table-fn"}   32.2±2.5(NR) [\*](#t002fn001){ref-type="table-fn"}    NA                                                    NA                                                NA                                                NA                                                NA                                                NA                                               NA                                              NA                                           NA                                           NA                                                   NA                                                   NA
  \[[@pone.0129274.ref030]\]                                                               34.9±2.8(R) [\*](#t002fn001){ref-type="table-fn"}    34.1±1.9(R) [\*](#t002fn001){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  2008                                SPVI                                                 34.8±2.8(NR) [\*](#t002fn001){ref-type="table-fn"}   35±2.4(NR) [\*](#t002fn001){ref-type="table-fn"}      NA                                                    NA                                                NA                                                NA                                                NA                                                NA                                               NA                                              NA                                           NA                                           NA                                                   NA                                                   NA
                                                                                           35.4±2.7(R) [\*](#t002fn001){ref-type="table-fn"}    38.4±2.8(R) [\*](#t002fn001){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Tops \[[@pone.0129274.ref026]\]     45±3(NR)                                             42±3(NR)                                             59±12(NR)                                             50±11(NR)                                             37±9(NR)                                          31±7(NR)                                          NA                                                NA                                                NA                                               NA                                              NA                                           NA                                           NA                                                   NA                                                   
  2006                                45±3(R)                                              48±3(R)                                              63±7(R)                                               68±8(R)                                               43±7(R)                                           47±7(R)                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Lemola                              NA                                                   NA                                                   115±39(NR)                                            97±35(NR)                                             NA                                                NA                                                NA                                                NA                                                NA                                               NA                                              NA                                           NA                                           NA                                                   NA                                                   
  \[[@pone.0129274.ref021]\] 2004                                                                                                               128±80(R)                                             135±70(R)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Tsao \[[@pone.0129274.ref025]\]     33.5±5.9(NR) [\*](#t002fn001){ref-type="table-fn"}   32.5±6.9(NR) [\*](#t002fn001){ref-type="table-fn"}   61.5±19.1(NR) [\*](#t002fn001){ref-type="table-fn"}   56.6±17.1(NR) [\*](#t002fn001){ref-type="table-fn"}   NA                                                NA                                                NA                                                NA                                                NA                                               NA                                              NA                                           NA                                           NA                                                   NA                                                   
  2005                                34.1±6.6(R) [\*](#t002fn001){ref-type="table-fn"}    36.2±6.4(R) [\*](#t002fn001){ref-type="table-fn"}    61.1±17.5(R) [\*](#t002fn001){ref-type="table-fn"}    78.7±25.3(R) [\*](#t002fn001){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

\* Paroxysmal Atrial Fibrillation

\# Persistent Atrial Fibrillation

& Chronic Atrial Fibrillation

NR = Not Recurrence; R = Recurrence; NA = Not Available

LAD = left atrial diameter; LAVmax = maximum left atrial volume; LAVmin = minimum left atrial volume; LAEF = left atrial ejective fraction; LAAEf = left atrial active ejective fraction; A wave = A wave velocity; A\' wave = A\' wave velocity

Other abbreviations and AF Recurrence defined as previously detailed.

All patients had underwent CA, one study \[[@pone.0129274.ref015]\] had repeated ablation. The majority of studies performed radiofrequency catheter ablation (RFCA), only one study \[[@pone.0129274.ref010]\] implemented cryoablation. Twelve studies \[[@pone.0129274.ref010], [@pone.0129274.ref012], [@pone.0129274.ref013], [@pone.0129274.ref017], [@pone.0129274.ref021], [@pone.0129274.ref022], [@pone.0129274.ref025], [@pone.0129274.ref026], [@pone.0129274.ref029]--[@pone.0129274.ref031], [@pone.0129274.ref033]\] had reported changes in LAD, LA volumes, or function on the basis of AF recurrence (AF recurrence defined as documented by body surface 12-lead electrocardiogram (ECG) or 24-hour Holter ECG lasting 30 seconds, despite being symptomatic or not, at any time from 3 months after CA \[[@pone.0129274.ref034]\]). Liu et al. \[[@pone.0129274.ref030]\] had compared two different treatment strategies \[circumferential pulmonary vein ablation (CPVA) vs. segmental pulmonary vein isolation (SPVI)\] on left atrial size in patients with lone paroxysmal AF (PAF). Nineteen studies \[[@pone.0129274.ref011], [@pone.0129274.ref012], [@pone.0129274.ref014]--[@pone.0129274.ref016], [@pone.0129274.ref018]--[@pone.0129274.ref024], [@pone.0129274.ref026]--[@pone.0129274.ref029], [@pone.0129274.ref031]--[@pone.0129274.ref033]\] had included patients with paroxysmal or non-paroxysmal AF, five studies \[[@pone.0129274.ref009], [@pone.0129274.ref010], [@pone.0129274.ref017], [@pone.0129274.ref025], [@pone.0129274.ref030]\] only included patients with PAF, one study \[[@pone.0129274.ref013]\] only included patients with persistent AF (PeAF), six studies \[[@pone.0129274.ref021], [@pone.0129274.ref023], [@pone.0129274.ref024], [@pone.0129274.ref026], [@pone.0129274.ref029], [@pone.0129274.ref032]\] included patients with permanent AF (only 49 enrolled patients). There were some co-morbidities including hypertension (HTN), diabetes mellitus (DM), and coronary artery disease (CAD) et al. in the majority of enrolled patients.

Quantitative Data Synthesis {#sec013}
---------------------------

The LAD (WMD, -0.91 mm; 95%CI, from -1.75 mm to -0.06 mm, *P* = 0.04; [Fig 2](#pone.0129274.g002){ref-type="fig"}), LAVmax (WMD, -6.48 mL; 95%CI, from -8.60 mL to -4.35 mL, *P* \< 0.00001; [Fig 3](#pone.0129274.g003){ref-type="fig"}), and LAVmin (WMD, -4.17 mL; 95%CI, from -6.21 mL to -2.13 mL, *P* \< 0.0001; [Fig 4](#pone.0129274.g004){ref-type="fig"}) were significantly decreased post-ablation, as compared with those pre-ablation. Nevertheless, a subgroup analysis was performed that was based on AF type; there were significant decreases in LA volumes (including LAVmax and LAVmin) for the AF patients. The LAD result indicated insignificant changes for patients with either paroxysmal or persistent AF (Figs [2](#pone.0129274.g002){ref-type="fig"}--[4](#pone.0129274.g004){ref-type="fig"}).

![A forest plot of comparison: changes in left atrial diameter (LAD) pre-ablation and post-ablation.](pone.0129274.g002){#pone.0129274.g002}

![A forest plot of comparison: changes in maximum left atrial volume (LAVmax) pre-ablation and post-ablation.](pone.0129274.g003){#pone.0129274.g003}

![A forest plot of comparison: changes in minimum left atrial volume (LAVmin) pre-ablation and post-ablation.](pone.0129274.g004){#pone.0129274.g004}

Compared with the pre-ablation outcomes, we found no significant differences in LAEF (WMD, 0.07%; 95%CI, from -2.22% to 2.36%, *P* = 0.95; [Fig 5](#pone.0129274.g005){ref-type="fig"}) and LAAEF (WMD, -1.86%; 95%CI, from -3.92% to 7.63%, *P* = 0.48; [Fig 6](#pone.0129274.g006){ref-type="fig"}). Subsequently, we performed a subgroup analysis based on the AF type, and there were insignificant differences among those studies with either PAF or PeAF, except for LAEF with PAF (WMD, -3.80%; 95%CI, from -6.65% to -0.95%, *P* = 0.009; [Fig 5](#pone.0129274.g005){ref-type="fig"}). Finally, we analyzed the A wave velocity (A) and A\' wave velocity (A\'), and there were insignificant differences during follow-up imaging for CA treatment, as compared with pre-ablation (Figs [7](#pone.0129274.g007){ref-type="fig"} and [8](#pone.0129274.g008){ref-type="fig"}).

![A forest plot of comparison: changes in left atrial ejective fraction (LAEF) pre-ablation and post-ablation.](pone.0129274.g005){#pone.0129274.g005}

![A forest plot of comparison: changes in left atrial active ejective fraction (LAAEF) pre-ablation and post-ablation.](pone.0129274.g006){#pone.0129274.g006}

![A forest plot of comparison: changes in A wave velocity pre-ablation and post-ablation.](pone.0129274.g007){#pone.0129274.g007}

![A forest plot of comparison: changes in A´ wave velocity pre-ablation and post-ablation.](pone.0129274.g008){#pone.0129274.g008}

Subsequently, we implemented a subgroup analysis on the basis of AF recurrence. There were significant decreased in LAD (WMD, -1.63 mm; 95%CI, from -3.01 mm to -0.24 mm, *P* = 0.02, [S1 Fig](#pone.0129274.s002){ref-type="supplementary-material"}), LAVmax (WMD, -7.53 mL; 95%CI, from -11.09 mL to -3.97 mL, *P* \< 0.0001, [S2 Fig](#pone.0129274.s003){ref-type="supplementary-material"}), and LAVmin (WMD, -6.73 mL; 95%CI, from -11.07 mL to -2.39 mL, *P* = 0.002, [S3 Fig](#pone.0129274.s004){ref-type="supplementary-material"}) with no recurrence AF during post-ablation follow-up, but not those with AF recurrence, except for LAD with AF recurrence (WMD, 2.25 mm; 95%CI, from 0.29 mm to 4.21 mm, *P* = 0.02, [S1 Fig](#pone.0129274.s002){ref-type="supplementary-material"}). The LAEF (WMD, -4.60%; 95%CI, from -7.91% to -1.29%, *P* = 0.006, [S4 Fig](#pone.0129274.s005){ref-type="supplementary-material"}) and LAAEF (WMD, -8.60%; 95%CI, from -13.46% to -3.74%, *P* = 0.0005, [S5 Fig](#pone.0129274.s006){ref-type="supplementary-material"}) were decreased significantly in patients with recurrence AF after CA during follow-up, however, there were insignificant changes between those with no recurrence AF.

Heterogeneity Analysis {#sec014}
----------------------

After performing a heterogeneity test, the existence of heterogeneity among those studies should not be ignored. To demonstrate the origin of the heterogeneity, a meta-regression analysis and sensitivity analysis were performed. Heterogeneity was significant in spite which individual study was excluded. As previously illustrated, a subgroup analysis was performed; each outcome was analyzed based on the AF type (PAF or PeAF). A random effects model was used to combine the effect size because significant heterogeneity was shown as an all-total consequence.

Subsequently, a sensitivity analysis that was on the basis of image modalities, the LAVmax (WMD, -9.31 mL; 95%CI, from -12.45 mL to -6.16 mL, *P* \< 0.00001, [S7 Fig](#pone.0129274.s008){ref-type="supplementary-material"}) and LAVmin (WMD, -6.07 mL; 95%CI, from -8.49 mL to -3.65 mL, *P* \< 0.00001, [S8 Fig](#pone.0129274.s009){ref-type="supplementary-material"}) remained significant decreased at post-ablation which detected by cardiac magnetic resonance imaging (CMR) and/or Computed Tomography (CT). However, the LAD (WMD, -0.77 mm; 95%CI, from -2.87 mm to 1.33 mm, *P* = 0.47, [S6 Fig](#pone.0129274.s007){ref-type="supplementary-material"}), LAEF (WMD, -0.28%; 95%CI, from -3.91% to 3.35%, *P* = 0.88, [S9 Fig](#pone.0129274.s010){ref-type="supplementary-material"}) and LAAEF (WMD, -2.47%; 95%CI, from -6.30% to 1.36%, *P* = 0.21, [S10 Fig](#pone.0129274.s011){ref-type="supplementary-material"}) were not significant change during follow-up after catheter ablation treatment. And then, we found that the LAVmax (WMD, -7.08 mL; 95%CI, from -12.52 mL to -1.64 mL, *P* = 0.01, [S7 Fig](#pone.0129274.s008){ref-type="supplementary-material"}), LAVmin (WMD, -4.07 mL; 95%CI, from -7.29 mL to -0.84 mL, *P* = 0.01, [S8 Fig](#pone.0129274.s009){ref-type="supplementary-material"}) and LAEF (WMD, -5.72%; 95%CI, from -11.02% to -0.42%, *P* = 0.03, [S9 Fig](#pone.0129274.s010){ref-type="supplementary-material"}) were significant decrease in PAF; the LAV (LAVmax: WMD, -8.90 mL; 95%CI, from -15.28 mL to -2.53 mL, *P* = 0.006, [S7 Fig](#pone.0129274.s008){ref-type="supplementary-material"}; LAVmin: WMD, -7.42 mL; 95%CI, from -13.59 mL to -1.25 mL, *P* = 0.02, [S8 Fig](#pone.0129274.s009){ref-type="supplementary-material"}) were decreased significantly in PeAF, however, the LAEF (WMD, 8.03%; 95%CI, from 2.81% to 13.24%, *P* = 0.003, [S9 Fig](#pone.0129274.s010){ref-type="supplementary-material"}) was increased significantly in PeAF.

According to a sensitivity analysis that was based on a follow-up of \>6 months, there were significant decreases in only LAV after catheter ablation therapy, including LAVmax (WMD, -6.07 mL; 95%CI, from -8.76 mL to -3.38 mL, *P* \< 0.00001, [S12 Fig](#pone.0129274.s013){ref-type="supplementary-material"}) and LAVmin (WMD, -3.91 mL; 95%CI, from -6.62 mL to -1.20 mL, *P* = 0.005; [S13 Fig](#pone.0129274.s014){ref-type="supplementary-material"}). However, the LAD, LAEF, and LAAEF did not significantly change during follow-up after ablation treatment (WMD, -0.81 mm; 95%CI, from -1.68 mm to 0.06 mm, P = 0.07; WMD, 0.05%; 95%CI, from -2.67% to 2.77%, *P* = 0.97; WMD, 2.89%; 95%CI, from -2.42% to 8.20%, *P* = 0.29; respectively, [S11](#pone.0129274.s012){ref-type="supplementary-material"}, [S14](#pone.0129274.s015){ref-type="supplementary-material"} and [S15](#pone.0129274.s016){ref-type="supplementary-material"} Figs).

A sensitivity analysis was performed based on a follow-up of \>12 months. After ablation therapy, the LAVmax (WMD, -7.83 mL; 95%CI, from -11.65 mL to -4.01 mL, *P* \< 0.0001, [S17 Fig](#pone.0129274.s018){ref-type="supplementary-material"}) and LAVmin (WMD, -5.90 mL; 95%CI, from -9.77 mL to -2.03 mL, *P* = 0.003, [S18 Fig](#pone.0129274.s019){ref-type="supplementary-material"}) were significantly decreased; however, the LAD and LAEF did not significantly change (WMD, -0.36 mm; 95%CI, from -1.53 mm to 0.81 mm, *P* = 0.55; WMD, 0.80%; 95%CI, from -3.03% to 4.63%, *P* = 0.68; respectively, [S16](#pone.0129274.s017){ref-type="supplementary-material"} and [S19](#pone.0129274.s020){ref-type="supplementary-material"} Figs).

Subsequently, a meta-regression analysis was performed to determine the heterogeneity origin. However, we did not find any factors that contributed to the heterogeneity.

Publication Bias Analysis {#sec015}
-------------------------

Egger's test and Begg's funnel plot were used to evaluate publication bias. There were no significant risks of publication bias according to an analysis using Stata 12.0 (the *P* value for each test was \>0.05; [Table 3](#pone.0129274.t003){ref-type="table"}). The funnel plot was generally symmetrical, and it indicated that the publication bias for the studies was controlled.

10.1371/journal.pone.0129274.t003

###### Assessment of publication bias with Stata 12.0 for each primary outcome.

![](pone.0129274.t003){#pone.0129274.t003g}

  Primary Outcome   Begg's Test (P value)   Egger's Test (P value)
  ----------------- ----------------------- ------------------------
  LAD               0.921                   0.636
  LAVmax            0.767                   0.832
  LAVmin            0.726                   0.670
  LAEF              0.785                   0.948
  LAAEF             1.000                   0.605
  A Wave            0.536                   0.205
  A\' Wave          0.086                   0.117

Abbreviations as previously detailed.

Discussion {#sec016}
==========

In the present review, we found that the LA volumes and LAD were significantly decreased after CA therapy during follow-up imaging. Nonetheless, we did not find any significant changes in LA function (included LAEF and LAAEF) after ablation treatment during follow-up imaging. Furthermore, there were significant decreases in the LA volumes and LAEF with paroxysmal AF after CA treatment. However, we did not find any significant changes in outcomes, as previously detailed, for persistent AF after ablation therapy, except for LA volumes.

CA is a therapeutic method for terminating the underlying electrophysiological mechanism of AF. The substrate and trigger foci are isolated by freezing (cryoablation) or radiofrequency energy and then terminate the electrical conduction from the pulmonary vein (PV) to LA. Currently, CA is approved by the Food and Drug Administration (FDA) for managing paroxysmal AF. Although this practical strategy is also used for managing non-paroxysmal AF, unfortunately, it is not yet approved by the FDA \[[@pone.0129274.ref002], [@pone.0129274.ref035]\]. The resumption of a sinus rhythm with CA is a perfect consequence, but the amount of LA scarring produced by CA could influence LA structural and functional remodeling, especially with repeated ablation. Structural remodeling includes increasing LA size and a change in LA strain. Several studies \[[@pone.0129274.ref010], [@pone.0129274.ref018], [@pone.0129274.ref019]\] reported that the enlargement could be reversed after successful ablation therapy that is defined as the maintenance of a sinus rhythm during follow-up \[[@pone.0129274.ref034]\]. Thus, LA reverse remodeling may become a robust sign of successful CA for patients with AF. Further studies should be conducted to evaluate the effects on LA function for patients with AF after a repeat ablation treatment.

There was a significant decrease in LAEF after CA treatment in studies with paroxysmal AF; however, we did not find similar outcomes in studies with persistent AF. Rodrigues et al. \[[@pone.0129274.ref017]\] reported a degradation in LAEF after CA for patients with paroxysmal AF at a follow-up duration of about 8 months after performing transthoracic echocardiography (TTE). Hof et al. \[[@pone.0129274.ref011]\] found a similar outcome using three-dimensional computed tomography (CT). However, Erdei et al. \[[@pone.0129274.ref010]\] and Machino-Ohtsuka et al. \[[@pone.0129274.ref013]\] described that the LAEF was preserved and even increased in patients without an AF recurrence at a follow-up of \>12 months; however, it had decreased in AF recurrence patients after TTE and CMR. Why did this phenomenon occur in these studies? Several reasons for this variance should be considered, including the follow-up duration after CA therapy; the chronicity of AF; the different clinical outcomes; and the different degrees of tissue damage related to the different ablation strategies, tools, or both.

More consideration should be given to the follow-up duration regarding studying LA function and size. Studies with a long follow-up (not less than 12 months) \[[@pone.0129274.ref012], [@pone.0129274.ref013], [@pone.0129274.ref019]\] have illustrated significant increases in LAEF after ablation treatment in AF patients; however, insignificant changes in LAEF with paroxysmal AF in 3 months follow-up \[[@pone.0129274.ref014], [@pone.0129274.ref016]\]. Further, a sensitivity analysis based on the follow-up duration was not persuasive because of a lack of detailed individual patient data. McGann et al. \[[@pone.0129274.ref036]\] reported that the quantification and detection of left atrial wall scarring would be applicable 3 months after CA in patients with AF. As we known, there is a phenomenon of atrial "stunning" during in 1 month follow-up after catheter ablation therapy, and either the LA size or the LA function is unstable change. After the "blanking period" (about 3 months), which the rate of recurrence AF is highest \[[@pone.0129274.ref037]\], the quantification and detection of LA size and function is more credible and accurate. Therefore, it is important that a longer follow-up duration should be performed for evaluating LA function. Moreover, because the LA function was assessed using only the sinus rhythm (SR), it is difficult to evaluate LA function in permanent AF patients.

In addition, the imaging technique is another important factor. Many different methods were performed in the studies, including TTE \[[@pone.0129274.ref009], [@pone.0129274.ref010], [@pone.0129274.ref013]--[@pone.0129274.ref015], [@pone.0129274.ref017]--[@pone.0129274.ref020], [@pone.0129274.ref022], [@pone.0129274.ref024], [@pone.0129274.ref026]--[@pone.0129274.ref032]\], CMR \[[@pone.0129274.ref011], [@pone.0129274.ref012], [@pone.0129274.ref016], [@pone.0129274.ref025], [@pone.0129274.ref033]\], and CT \[[@pone.0129274.ref014], [@pone.0129274.ref021], [@pone.0129274.ref023], [@pone.0129274.ref027]\]. As an established method in cardiac imaging modalities, TTE can identify the size of each chamber, as well as the ejection fraction of the LA and left ventricle (LV). However, a limitation occurs if patients are obese and have serious obstructive pulmonary disease with poor acoustic windows \[[@pone.0129274.ref038]\]. Multidetector Computed Tomography (MDCT) has a prominent temporal and spatial resolution for measuring LA volumes. CMR can concurrently discover pre-ablation fibrosis and post-ablation scar tissue and measure PV anatomy in patients who undergo CA therapy \[[@pone.0129274.ref039]\]. As we known, different analytical methods or image tools would obtain different results. Compare to TTE, using CMR and CT have a prominent temporal and spatial resolution for measuring LA volumes and EF, the results of CMR or CT should be more accurate than that of TEE. Due to this important issue, we performed subgroup analysis based on the variant methods of image. Subsequently, after excluding studies using TTE, only 9 studies (enrolled 635 patients) \[[@pone.0129274.ref011], [@pone.0129274.ref012], [@pone.0129274.ref014], [@pone.0129274.ref016], [@pone.0129274.ref021], [@pone.0129274.ref023], [@pone.0129274.ref025], [@pone.0129274.ref027], [@pone.0129274.ref033]\] were included in the subgroup analysis on the basis of detecting by CMR and/or CT. The LA volumes significantly decreased, LAEF/LAAEF insignificant changed. The explanations for this phenomenon as follow. First, CMR and CT/MDCT are more accuracy and improve reproducibility in measurement of LA volumes and functions compare to TTE. Second, the numbers of included studies were decreased, and then it may influence the pooled data. Therefore, compared with MDCT and CMR, TTE may underestimate the true LA size and function.

Nonetheless, there is no gold standard for measuring LA function. In the present review, the LAEF was used to define LA function in 15 studies \[[@pone.0129274.ref010]--[@pone.0129274.ref017], [@pone.0129274.ref019], [@pone.0129274.ref023], [@pone.0129274.ref027]--[@pone.0129274.ref029], [@pone.0129274.ref031], [@pone.0129274.ref033]\], and only 6 studies used LAAEF to define LA function \[[@pone.0129274.ref011], [@pone.0129274.ref015], [@pone.0129274.ref016], [@pone.0129274.ref024], [@pone.0129274.ref029], [@pone.0129274.ref031]\]. Furthermore, A wave velocity \[[@pone.0129274.ref009], [@pone.0129274.ref013], [@pone.0129274.ref017], [@pone.0129274.ref027]--[@pone.0129274.ref029], [@pone.0129274.ref032]\] and A\' wave velocity \[[@pone.0129274.ref010], [@pone.0129274.ref017], [@pone.0129274.ref028], [@pone.0129274.ref032]\] were used to define LA contractile function. The A wave velocity involves the peak velocities of the late transmitral flow, as measured by pulsed-wave DE, reflecting LA systolic function from hemodynamics, but it is not sensitive because it can be affected by the LV diastolic function and preload. However, compared with the A wave velocity, the A\' wave velocity, as detailed previously, is an easy and effective means to assess LA systolic function from tissue motion because it is correlated with changes in the LA systolic area and volume \[[@pone.0129274.ref008]\]. Therefore, further studies should be conducted to assess this method for evaluating LA function.

Beyond these, the treatment strategy and energy of catheter ablation are another factor. In this meta-analysis, the majority of included studies were used RFCA, only one study \[[@pone.0129274.ref010]\] performed cryoablation. As we known, different treatment strategies, such as SPVI and PVAI, lead to different outcomes, and diverse ablation temperature and power resulted in different damages for atrium. The included studies used RFCA were set at a similar value of the ablation temperature and power, and therefore, the results have consistency and comparability. After excluding the study performed cryoablation, there were similar pooled data compare to previous detailed. Due to there was no more available data, further studies should be focused on evaluating the effects on LA function and size for patients with AF after cryoablation treatment.

Heterogeneity is an important issue for explaining the outcomes of this review, and significant heterogeneity was found in this meta-analysis. Subsequently, sensitivity analyses were performed, and heterogeneity was significant in spite which individual study was excluded. We did not find any contributing factor for the heterogeneity with a meta-regression. The quality of the included articles may be the origin of heterogeneity.

Moreover, our review had some limitations. First, we did not consider any randomized control trial in this meta-analysis; the sample sizes of the included studies were small, and most were single center and either a prospective or retrospective study that may have added potential biases to such studies. Second, it is difficult to draw decisive conclusions regarding LA functional change after ablation therapy, because of inconsistencies regarding individual patient data, the imaging method, and the follow-up duration. Third, although publication bias was not significant after performing an Egger's test and a Begg's funnel plot, the influence of bias in this article could not be thoroughly excluded, as only studies published in English were included. Forth, we have tried addressing an issue but indirectly regarding the effectiveness of CA for AF by looking at LA size and function, however, it is a pooled data and it has its own set of issues which precludes us from providing any more clarity. Moreover, another limitation is the lack of a gold standard to measure LA function among these involved studies. Currently, MDCT and CMR are considered relatively accurate methods for measuring LA function and size. Finally, although several studies reported that the LA volumes and sizes are predictors of AF recurrence after CA therapy \[[@pone.0129274.ref040]--[@pone.0129274.ref042]\], our review did not perform an analysis based on AF recurrence in different types of AF. Therefore, we do not know the relationship between AF recurrence and LA function/size among different types of AF.

In conclusion, With CA, LA volumes and LAD were decreased significantly in patients with AF; LAEF was not significant changes in patients with PeAF but decreased in those with PAF.
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